IFN‑&gamma; induces apoptosis in gemcitabine‑resistant pancreatic cancer cells

Kong,Xiangxin; Cheng,Denglong; Xu,Xu; Zhang,Yuan; Li,Xin; Pan,Wanlong

doi:10.3892/mmr.2024.13200

IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells

Authors:
- Xiangxin Kong
- Denglong Cheng
- Xu Xu
- Yuan Zhang
- Xin Li
- Wanlong Pan
View Affiliations

Affiliations: Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China, Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
Published online on: March 14, 2024 https://doi.org/10.3892/mmr.2024.13200
Article Number: 76
Copyright: © Kong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent and aggressive form of pancreatic cancer. Gemcitabine (GEM), the first‑line treatment for PDAC, which alleviates symptoms and enhances the quality of life of patients. However, it is prone to lead to the development of drug resistance during treatment. Interferon (IFN)‑γ exhibits antitumor and immunomodulatory properties. The present study aimed to explore the impact of IFN‑γ on the viability, migration and apoptosis of GEM‑resistant pancreatic cancer cells. Firstly, a GEM‑resistant pancreatic cancer cell line, named PANC‑1/GEM, was constructed. Hematoxylin and eosin staining analyzed the cell morphology, whereas reverse transcription‑quantitative PCR (RT‑qPCR) assessed the expression levels of the drug‑resistance genes multidrug resistance‑associated protein (MRP) and breast cancer resistance protein (BCRP). The MTT assay and cell counting techniques were used to determine the appropriate concentration of IFN‑y and its effects on cell viability. The IFN‑γ‑induced apoptosis of PANC‑1/GEM cells was assessed using an Apoptosis Detection Kit, whereas the impact of IFN‑γ on the migration of these cells was evaluated using a wound‑healing assay. The MTT assay revealed a resistance index of 22.4 in the PANC‑1/GEM cell line. RT‑qPCR indicated that, compared with in wild‑type cells, the PANC‑1/GEM resistant strain exhibited lower MRP and higher BCRP mRNA expression levels. The optimal concentration of IFN‑γ for affecting PANC‑1/GEM cells was determined to be 0.3 µg/ml. At this concentration, IFN‑γ induced PANC‑1/GEM cell apoptosis, along with a notable reduction in migration. Following treatment of PANC‑1/GEM cells with IFN‑γ, MRP expression increased whereas BCRP mRNA expression decreased, indicating a reversal in their drug‑resistance gene expression. In conclusion, IFN‑γ exhibited antitumor immune properties by upregulating MRP and downregulating BCRP expression, reversing drug‑resistance gene expression, and reducing cell viability and migration, while promoting apoptosis in PANC‑1/GEM cells. IFN‑γ could potentially serve as a treatment option for patients with GEM‑resistant pancreatic cancer.

View Figures

View References

1	Luchini C, Grillo F, Fassan M, Vanoli A, Capelli P, Paolino G, Ingravallo G, Renzulli G, Doglioni C, D'Amuri A, et al: Malignant epithelial/exocrine tumors of the pancreas. Pathologica. 112:210–226. 2020. View Article : Google Scholar : PubMed/NCBI
2	Haeberle L and Esposito I: Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 4:502019. View Article : Google Scholar : PubMed/NCBI
3	Lu H, Niu F, Liu F, Gao J, Sun Y and Zhao X: Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 6:1181–1191. 2017. View Article : Google Scholar : PubMed/NCBI
4	Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, Zhang X, Huang Y, Zhang R, Wei J, et al: LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes. Mol Cancer. 19:1182020. View Article : Google Scholar : PubMed/NCBI
5	Wu Z, Li S and Zhu X: The mechanism of stimulating and mobilizing the immune system enhancing the anti-tumor immunity. Front Immunol. 12:6824352021. View Article : Google Scholar : PubMed/NCBI
6	McDonald OG: The biology of pancreatic cancer morphology. Pathology. 54:236–247. 2022. View Article : Google Scholar : PubMed/NCBI
7	Amrutkar M and Gladhaug IP: Pancreatic cancer chemoresistance to gemcitabine. Cancers. 9:1572017. View Article : Google Scholar : PubMed/NCBI
8	Castro F, Cardoso AP, Gonçalves RM, Serre K and Oliveira MJ: Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 9:8472018. View Article : Google Scholar : PubMed/NCBI
9	Narayanan P, Farghadani R, Nyamathulla S, Rajarajeswaran J, Thirugnanasampandan R and Bhuwaneswari G: Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line. J Biochem Mol Toxicol. 36:e230082022. View Article : Google Scholar : PubMed/NCBI
10	He J, Bugde P, Li J, Biswas R, Li S, Yang X, Tian F, Wu Z and Li Y: Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca-2 and PANC-1 cells. Oncol Rep. 51:72024. View Article : Google Scholar : PubMed/NCBI
11	Chen M, He M, Song Y, Chen L, Xiao P, Wan X, Dai F and Shen P: The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. Int J Mol Med. 34:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
12	Nowak AK, Robinson BW and Lake RA: Gemcitabine exerts a selective effect on the humoral immune response: Implications for combination chemo-immunotherapy. Cancer Res. 62:2353–2358. 2002.PubMed/NCBI
13	Zhang QB, Ye RF, Ye LY, Zhang QY and Dai NG: Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells. Am J Transl Res. 12:3702–3714. 2020.PubMed/NCBI
14	Liu L, Yang L, Chang H, Chen YN, Zhang F, Feng S, Peng J, Ren CC and Zhang XA: CP-31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression. Int J Oncol. 54:942–954. 2019.PubMed/NCBI
15	Zhu F, Wu Q, Ni Z, Lei C, Li T and Shi Y: miR-19a/b and MeCP2 repress reciprocally to regulate multidrug resistance in gastric cancer cells. Int J Mol Med. 42:228–236. 2018.PubMed/NCBI
16	Zhu K, Fang W, Chen Y, Lin S and Chen X: TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer. Oncol Rep. 32:1234–1242. 2014. View Article : Google Scholar : PubMed/NCBI
17	Wang B, Shen C, Li Y, Zhang T, Huang H, Ren J, Hu Z, Xu J and Xu B: Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling. Onco Targets Ther. 12:5751–5765. 2019. View Article : Google Scholar : PubMed/NCBI
18	Zhou Y, Zhou Y, Yang M, Wang K, Liu Y, Zhang M, Yang Y, Jin C, Wang R and Hu R: Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. Redox Biol. 22:1011312019. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Pekarek L, Fraile-Martinez O, Garcia-Montero C, Saez MA, Barquero-Pozanco I, Del Hierro-Marlasca L, de Castro Martinez P, Romero-Bazán A, Alvarez-Mon MA, Monserrat J, et al: Clinical applications of classical and novel biological markers of pancreatic cancer. Cancers. 14:18662022. View Article : Google Scholar : PubMed/NCBI
21	Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM and George TJ Jr: Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. Cancer Med. 4:1224–1239. 2015. View Article : Google Scholar : PubMed/NCBI
22	Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG and Rana A: The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front Oncol. 11:6883772021. View Article : Google Scholar : PubMed/NCBI
23	Fraile-Martinez O, García-Montero C, Pekarek L, Saz JV, Álvarez-Mon MÁ, Barrena-Blázquez S, García-Honduvilla N, Buján J, Asúnsolo Á, Coca S, et al: Decreased survival in patients with pancreatic cancer may be associated with an increase in histopathological expression of inflammasome marker NLRP3. Histol Histopathol. 39:35–40. 2024.PubMed/NCBI
24	Ortega MA, Fraile-Martinez O, Pekarek L, García-Montero C, Alvarez-Mon MA, Castellanos AJ, García-Honduvilla N, Buján J, Alvarez-Mon M, Sáez MA, et al: Oxidative stress markers are associated with a poor prognosis in patients with pancreatic cancer. Antioxidants (Basel). 11:7592022. View Article : Google Scholar : PubMed/NCBI
25	Jorgovanovic D, Song M, Wang L and Zhang Y: Roles of IFN-γ in tumor progression and regression: A review. Biomark Res. 8:492020. View Article : Google Scholar : PubMed/NCBI
26	Xin L, Xiao W, Che L, Liu J, Miccio L, Bianco V, Memmolo P, Ferraro P, Li X and Pan F: Label-free assessment of the drug resistance of epithelial ovarian cancer cells in a microfluidic holographic flow cytometer boosted through machine learning. ACS Omega. 6:31046–31057. 2021. View Article : Google Scholar : PubMed/NCBI
27	Patel H, Wu ZX, Chen Y, Bo L and Chen ZS: Drug resistance: From bacteria to cancer. Mol Biomed. 2:272021. View Article : Google Scholar : PubMed/NCBI
28	Qin T, Chen K, Li J, Qian W, Xiao Y, Wu E, Ma J, Chen Z, Wang Z, Ma Q and Wu Z: Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Biomed Pharmacother. 148:1127132022. View Article : Google Scholar : PubMed/NCBI
29	Miller DW, Fontain M, Kolar C and Lawson T: The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett. 107:301–306. 1996. View Article : Google Scholar : PubMed/NCBI
30	Washio I, Nakanishi T, Ishiguro N, Yamamura N and Tamai I: Impact of breast cancer resistance protein expression on the in vitro efficacy of anticancer drugs in pancreatic cancer cell lines. Drug Metab Dispos. 46:214–222. 2018. View Article : Google Scholar : PubMed/NCBI
31	Mojic M, Takeda K and Hayakawa Y: The dark side of IFN-γ: Its role in promoting cancer immunoevasion. Int J Mol Sci. 19:892017. View Article : Google Scholar : PubMed/NCBI